| 舒尼替尼治疗伊马替尼耐药晚期胃肠间质瘤的药物经济学评价 |
| |
| 引用本文： | 王越,吴建华,吴东方.舒尼替尼治疗伊马替尼耐药晚期胃肠间质瘤的药物经济学评价[J].药物流行病学杂志,2021(1):33-38. |
| |
| 作者姓名： | 王越 吴建华 吴东方 |
| |
| 作者单位： | 武汉大学中南医院药学部 |
| |
| 基金项目： | 国家自然科学基金项目（编号:81570417）； |
| |
| 摘 要： | 目的:比较舒尼替尼和大剂量伊马替尼用于既往伊马替尼治疗耐药的晚期胃肠间质瘤患者的二线治疗的成本-效果。方法:基于Ⅲ期临床试验的研究数据,结合我国相关药物和不良反应治疗成本,利用TreeAge软件建立Markov模型,对两种用药方案进行成本-效果分析。结果:进口药组大剂量伊马替尼和舒尼替尼方案的成本-效果比分别为45 806.19元/质量调整生存月(QALM)和20 330.79元/QALM,计算得到增量成本-效果比超出意愿支付阈值,舒尼替尼为优势药物。国产药组大剂量伊马替尼和舒尼替尼方案的成本-效果比分别为5 855.50元/QALM和15 101.70元/QALM,伊马替尼为优势药物。敏感性分析的结果与成本-效果分析一致。结论:对于伊马替尼耐药的晚期胃肠间质瘤患者,进口药组舒尼替尼治疗比大剂量伊马替尼治疗具有更好的经济性,但在国产药组中大剂量伊马替尼比舒尼替尼治疗具有经济学优势。
|
| 关 键 词： | 舒尼替尼 伊马替尼 胃肠间质瘤 成本-效果分析 药物经济学 |
Pharmacoeconomic Evaluation of Sunitinib in the Treatment of Imatinib-resistant Advanced Gastrointestinal Stromal Tumors |
| |
| Wang Yue,Wu Jianhua,Wu Dongfang.Pharmacoeconomic Evaluation of Sunitinib in the Treatment of Imatinib-resistant Advanced Gastrointestinal Stromal Tumors[J].Chinese Journal of Pharmacoepidemiology,2021(1):33-38. |
| |
| Authors: | Wang Yue Wu Jianhua Wu Dongfang |
| |
| Affiliation: | (Department of Pharmacy,Zhongnan Hospital of Wuhan University,Wuhan 430071,China) |
| |
| Abstract: | Objective:To evaluate the cost-effectiveness of sunitinib compared with high does of imatinib in the second-line treatment of imatinib-resistant patients with advanced gastrointestinal stromal tumors after prior imatinib therapy.Methods:The clinical parameters were obtained from the phase Ⅲ clinical trial;combined with the treatment cost of domestic related drugs and adverse reaction therapy. Markov model was established by using TreeAge software, and pharmacoeconomic evaluation was conducted by means of cost-effectiveness analysis for two treatment schemes. Results:High dose of imatinib provided the cost-effectiveness ratio of 45 806.19 yuan/quality adjusted life month(QALM) in the imported drug group, which sunitinib provided the ratio of 20 330.79 yuan/QALM, resulting in that the incremental cost-effectiveness ratio was greater than willingness-to-pay threshold. The results showed that imported sunitinib was the dominant drugs. In the domestic drug group, imatinib provided the cost-effectiveness ratio of 5 855.50 yuan/QALM which sunitinib provided the ratio of 15 101.70 yuan/QALM, resulting in that the domestic imatinib was the dominant drugs. Result of sensitivity analysis was consistent with the cost-effectiveness analysis.Conclusion:For imatinib-resistant patients with advanced gastrointestinal stromal tumors, sunitinib treatment was more economical than high dose of imatinib treatment in the imported drug group. But in the domestic drug group, high dose of imatinib treatment had economic advantages compared with sunitinib treatment. |
| |
| Keywords: | Sunitinib Imatinib Gastrointestinal stromal tumours Cost-effectiveness analysis Pharmacoeconomics |
| 本文献已被 维普 等数据库收录！ |
|
